Publications by authors named "Jung-Young Kim"

Radiolabeled antibodies are promising for targeted cancer imaging, but their structural integrity may suffer during bioconjugation and radiolabeling, leading to undetected aggregation. This study evaluates dynamic light scattering (DLS) as a complementary method to size-exclusion high-performance liquid chromatography (SEC-HPLC) for detecting aggregation in radiolabeled antibodies. Trastuzumab was conjugated with a NOTA bifunctional chelator at various ratios, radiolabeled with [Cu]CuCl, and analyzed by using DLS and SEC-HPLC before and after purification.

View Article and Find Full Text PDF

Background: Primary brain tumors (PBTs) pose a significant health challenge, affecting patients and their caregivers. While early integration of palliative care (PC) has shown benefits in advanced cancer, its integration for PBT patients, particularly glioblastoma (GBM) patients, remains complex. We hypothesized that our previous PC integration efforts may have failed due to knowledge-gaps and misconceptions among patients, caregivers, and providers.

View Article and Find Full Text PDF

The study introduces a novel maleamate-based prosthetic group specifically designed for efficient, site-specific radioiodination of biomolecules that contain or are modified with cysteine residues. This strategy is a compelling alternative to the conventional maleimide-based approach, demonstrating outstanding attributes such as high radiochemical yield, rapid reaction kinetics, applicability in aqueous media at neutral pH, and exceptional stability under a competitive environment.

View Article and Find Full Text PDF

Radiolabeling of biomolecules and cells with radiolabeled prosthetic groups has significant implications for nuclear medicine, imaging, and radiotherapy. Achieving site-specific and controlled incorporation of radiolabeled prostheses under mild reaction conditions is crucial for minimizing the impact on the bioactivity of the radiolabeled compounds. The targeting of natural and abundant amino acids during radiolabeling of biomolecules often results in nonspecific and uncontrolled modifications.

View Article and Find Full Text PDF

The burgeoning interest in developing boron neutron capture therapy (BNCT) tracers and their accompanying diagnostics for the treatment of recalcitrant tumors has prompted this investigation. Our study aims to devise a tumor treatment strategy utilizing BNCT to target the αβ integrin. To this end, we propose a pioneering boron-infused cyclic Arg-Gly-Asp (RGD) peptide, cRGD(d-BPA)K, designed as an efficacious BNCT tracer.

View Article and Find Full Text PDF

4-Nonylphenol (4NP) is concerning due to its growing presence and endocrine-disrupting nature, raising concerns about its impact on health. In this study I-labeled 4NP was synthesized for tracing. Positron emission tomography imaging and biodistribution studies showed significant accumulation in various tissues after oral or intraperitoneal administration, emphasizing its intricate distribution and potential long-term effects, crucial for future risk assessments.

View Article and Find Full Text PDF

Toxic fission products, such as cesium (Cs) and iodine (I) are of great concern because of their long half-lives and high solubility in water. The simultaneous removal of Cs and I using a single adsorbent is an area of increasing interest. In this study, MXene/silver nanowire (AgNW) composite was synthesized through physical mixing and employed for simultaneous removal of iodide (I) and cesium (Cs) ions from contaminated water.

View Article and Find Full Text PDF
Article Synopsis
  • PET and SPECT are cool imaging technologies that help look at how medicine works in the body without needing surgery.* -
  • Boron neutron capture therapy (BNCT) is a special cancer treatment that targets tumor cells while leaving healthy cells alone, which is super important for reducing side effects.* -
  • For BNCT to work well, scientists need to put enough boron in the tumor, and this review talks about ways to track how effective the boron delivery is using PET or SPECT.*
View Article and Find Full Text PDF

The aim of this study is to evaluate a radioactive metal complex platform for brain tumor targeting. Herein, we introduce a new porphyrin derivative, 5,10,15,20-(tetra-,-dimethyl-4-aminophenyl)porphyrin (TDAP), in which four ,-dimethyl-4--phenylenediamine (DMPD) moieties are conjugated to the porphyrin labeled with the radiometal Cu. DMPD affected the pharmacokinetics of porphyrin in terms of retention time in vivo and tumor-targeting ability relative to those of unmodified porphyrin.

View Article and Find Full Text PDF

Early diagnosis of radiation-induced pulmonary fibrosis (RIPF) in lung cancer patients after radiation therapy is important. A gastrin-releasing peptide receptor (GRPR) mediates the inflammation and fibrosis after irradiation in mice lungs. Previously, our group synthesized a GRPR-targeted positron emission tomography (PET) imaging probe, [Cu]Cu-NODAGA-galacto-bombesin (BBN), an analogue peptide of GRP.

View Article and Find Full Text PDF

Over the last decade, Cu-labeling of monoclonal antibody (mAb) via inverse electron demand Diels-Alder click chemistry (IEDDA) have received much attention. Despite the tetrazine-transcyclooctene (Tz-TCO) click chemistry's convenience and efficiency in mAb labeling, there is limited information about the ideal parameters in the development of click chemistry mediated (radio)immunoconjugates. This encourages us to conduct a systematic optimization while concurrently determining the physiochemical characteristics of the model mAb, trastuzumab, and TCO conjugates.

View Article and Find Full Text PDF
Article Synopsis
  • Boron neutron capture therapy (BNCT) is an advanced treatment that specifically targets and damages cancer cells that absorb boron, making the drug's effectiveness reliant on the boron levels in tumors compared to normal tissue.
  • The compound 4-(benzo[]thiazol-2-yl)phenylboronic acid (BTPB) demonstrates strong ability to penetrate the blood-brain barrier and accumulate in brain tissue, achieving high boron concentrations necessary for effective BNCT.
  • BTPB has shown promising tumor-targeting capabilities in a glioma model, and this study evaluates its biological performance against another BNCT drug, boronophenylalanine.
View Article and Find Full Text PDF
Article Synopsis
  • - Photodynamic therapy (PDT) has limitations due to light penetration, restricting its effectiveness to only surface-level cancers, but researchers have discovered that Cerenkov luminescence from radioisotopes can be used as an alternative activation method for PDT without needing external light.
  • - The study combines clinically available agents, 5-aminolevulinic acid (5-ALA) and Cu-DOTA-trastuzumab, which target cancer cells selectively, to enhance tumor-specific energy transfer for improved PDT.
  • - Results demonstrate substantial cytotoxicity and tumor reduction in HER2-expressing breast and gastric cancer models, suggesting that this dual-targeted, Cerenkov luminescence-based treatment has strong potential for future
View Article and Find Full Text PDF
Article Synopsis
  • Hepsin is a serine protease that is highly expressed in prostate cancer, making it a potential biomarker for detection, as opposed to normal prostate tissue.
  • The study involved creating a PET imaging radioligand by synthesizing six derivatives and selecting the most effective one based on its ability to bind to hepsin.
  • The developed [Cu] radioligand showed strong binding to prostate cancer cells in mice, particularly in those with 22Rv1 tumors, indicating its potential for imaging hepsin in prostate cancer.
View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) does not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Because TNBC lacks the expression of commonly targeted receptors, it is challenging to develop a new imaging agent for this cancer subtype. Heterogeneous nuclear ribonucleoproteins (hnRNPs) are RNA-protein complexes that have been linked to tumor development and progression.

View Article and Find Full Text PDF

While boron neutron capture therapy (BNCT) depends primarily on the short flight range of the alpha particles emitted by the boron neutron capture reaction, gadolinium neutron capture therapy (GdNCT) mainly relies on gamma rays and Auger electrons released by the gadolinium neutron capture reaction. BNCT and GdNCT can be complementary in tumor therapy. Here, we studied the combined effects of BNCT and GdNCT when boron and gadolinium compounds were co-injected, followed by thermal neutron irradiation, and compared these effects with those of the single therapies.

View Article and Find Full Text PDF

Immuno-positron emission tomography (PET) has great potential to evaluate the target expression level and therapeutic response for targeted cancer therapy. Immuno-PET imaging with pertuzumab, due to specific recognition in different binding sites of HER2, could be useful for the determination of the therapeutic efficacy of HER2-targeted therapy, trastuzumab, and heat shock protein 90 (HSP90) inhibitor, in HER2-expressing breast cancer. The aim of this study is to evaluate the feasibility of monitoring therapeutic response with Zr-DFO-pertuzumab for the treatment of HER2-targeted therapeutics, trastuzumab, or the HSP90 inhibitor 17-DMAG, in trastuzumab-resistant JIMT-1 breast cancer models.

View Article and Find Full Text PDF

Purpose: Hydrogen sulfide (HS) plays important roles in brain pathophysiology. However, nuclear imaging probes for the in vivo detection of brain HS in living animals have not been developed. Here, we report the first nuclear imaging probe that enables in vivo imaging of endogenous HS in the brain of live mice.

View Article and Find Full Text PDF

Immuno-positron emission tomography (immuno-PET) is a rapidly growing imaging technique in which antibodies are radiolabeled to monitor their in vivo behavior in real time. However, effecting the controlled conjugation of a chelate-bearing radioactive atom to a bulky antibody without affecting its immunoreactivity at a specific site is always challenging. The in vivo stability of the radiolabeled chelate is also a key issue for successful tumor imaging.

View Article and Find Full Text PDF

The aim of this work was to evaluate a tumor-targeting porphyrin-based gadolinium complex (Gd-TDAP) for use as an MR/optical imaging agent and potential therapeutic agent. Gd-TDAP had higher longitudinal relaxivity (11.8 mM s) than a commercial MRI contrast agent (Omniscan; 3.

View Article and Find Full Text PDF

Most nanoparticles show much higher uptake in mononuclear phagocyte system (MPS) organs than in tumors, which has been a long-lasting dilemma in nanomedicine. Here, we report an imaging strategy that selectively decreases MPS organ uptakes by utilizing the differential esterase activity in tumors and other organs. When an esterase-labile radiotracer loaded liposome was injected into the body, radioactivity was rapidly excreted from the liver and spleen after breakage of the ester bond by esterase.

View Article and Find Full Text PDF

Correction for 'A short PEG linker alters the in vivo pharmacokinetics of trastuzumab to yield high-contrast immuno-PET images' by Woonghee Lee et al., J. Mater.

View Article and Find Full Text PDF

Plastics are used commonly in the world because of their convenience and cost effectiveness. Microplastics, an environmental threat and human health risk, are widely detected in food and consequently ingested. However, degraded plastics are found everywhere, creating an environmental threat and human health risk.

View Article and Find Full Text PDF

Gadolinium neutron capture therapy (GdNCT) is a form of binary radiotherapy. It utilizes nuclear reactions that occur when gadolinium-157 is irradiated with thermal neutrons, producing high-energy γ-rays and Auger electrons. Herein, we evaluate the potential of GdNCT for cancer treatment using PEGylated liposome incorporated with an FDA-approved MRI contrast agent.

View Article and Find Full Text PDF

Objective: Several studies supported the usefulness of "the surprise question" in terms of 1-year mortality of patients. "The surprise question" requires a "Yes" or "No" answer to the question "Would I be surprised if this patient died in [specific time frame]." However, the 1-year time frame is often too long for advanced cancer patients seen by palliative care personnel.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionvt9aeukitjiicon15d00fln4qvt4lp03): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once